Human Prostate specific Antigen/KLK3 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.01 pg/ml (50 μl)；1.17 pg/ml (10 μl)； |
| Standard Curve Range | 1.37~1000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120 min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0113 | 0.0123 | 0.0118 | |
| 1.37 | 0.0313 | 0.0287 | 0.0300 | 0.0182 |
| 4.12 | 0.0555 | 0.0583 | 0.0569 | 0.0451 |
| 12.35 | 0.1327 | 0.1522 | 0.1425 | 0.1307 |
| 37.04 | 0.4008 | 0.3970 | 0.3989 | 0.3871 |
| 111.11 | 0.9790 | 0.9796 | 0.9793 | 0.9675 |
| 333.33 | 2.1300 | 2.0950 | 2.1125 | 2.1007 |
| 1000.00 | 3.1530 | 3.1460 | 3.1495 | 3.1377 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 22.47 | 110.77 | 353.24 | 26.24 | 124.90 | 268.61 |
| Standard Deviation | 0.59 | 3.83 | 13.52 | 0.84 | 2.86 | 13.52 |
| Coefficient of Variation(%) | 2.6 | 3.5 | 3.8 | 3.2 | 2.3 | 5.0 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human Prostate specific Antigen/KLK3 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 105% to 125% with an overall mean recovery of 115%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | n.d.-169.70 | 93.75 | 13.29 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of Prostate specific Antigen/KLK3 in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: Prostate specific Antigen/KLK3
The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.
Human plasma kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma bound to high molecular weight (HMW) kininogen or as a free zymogen. Once activated by its physiological activator, coagulation factor XII, it displays endopeptidase activity towards peptide bonds after arginine (preferred) and lysine. It cleaves HMW kininogen, its major physiological substrate, to release the potent vasodilator peptide bradykinin. It is also able to cleave a number of inactive precursor proteins to generate active products, such as plasminogen and prourokinase.
